Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Prospect of Rheumatoid Arthritis Prevention

Samantha C. Shapiro, MD  |  Issue: May 2024  |  May 6, 2024

Rheumatoid arthritis (RA) is treatable, and for that, we should be grateful. But wouldn’t it be better if we could prevent it from even happening? Recent data from a study in China demonstrated some interesting results. Could an older type of diabetes medication be the answer we’ve been looking for?

Background

Preclinical studies have suggested that thiazolidinediones (TZDs) have a protective effect against RA, but evidence from population-based studies to support this is scarce. TZDs are agonists of peroxisome proliferator-activated receptor gamma (PPARgamma), which is involved in the regulation of glucose homeostasis and lipid metabolism. PPARgamma also plays an important role in the control of inflammation, immune regulation and inhibition of apoptosis and oxidative stress, all of which have been shown to be associated with the pathogenesis of RA in animal models.1-3

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Researchers in China conducted a retrospective, population-based cohort study to assess the association between the use of TZDs and the incidence of RA in patients with type 2 diabetes mellitus (DM).4 The study was published online ahead of print in December 2023.

The primary outcome of the trial was incident cases of RA. This was defined as an RA diagnosis code followed by a second RA diagnosis code or a prescription of a disease-modifying anti-rheumatic drug (DMARD) within one year of the first diagnosis. This approach has been validated by previous research, demonstrating a positive predictive value of 89 to 97% for a true RA diagnosis.5,6

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Summary of Research

Zhao et al. used data from an electronic healthcare database in the Yinzhou District, Ningbo City, China, a highly urbanized region. The database integrates longitudinal information from electronic medical records, disease surveillance and management systems (including a diabetes registry and follow-up system), death registry and other healthcare services.

The final cohort included about 72,000 patients with type 2 DM who were either new TZD users or new alpha-glucosidase inhibitor (AGI) users (control group). TZDs included pioglitazone and rosiglitazone. AGIs included acarbose, miglitol and voglibose. TZDs and AGIs are among the top four most commonly prescribed medications for people with type 2 DM in China; only metformin and insulin secretagogues are prescribed more frequently.7

Patients were Chinese, aged 18 years or older with type 2 DM. The majority were around 60 years of age, with equal representation of men and women. Patients were excluded if they initiated combination therapy with TZDs and AGIs, or if they had received a diagnosis of arthritis or spondylitis prior to the index date of the study.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ConditionsDrug UpdatesResearch ReviewsResearch RheumRheumatoid Arthritis Tagged with:preventionRA Resource Centerthiazolidinediones

Related Articles

    Rheumatology in China from Its Beginning to Today

    October 18, 2018

    Rheumatology in China is a relatively young discipline, but it has developed exponentially over the past three decades. In this article, we review the history of rheumatology in China and advances in clinical care, research and education in this field. The Founding Father Naizheng Zhang, MD, is widely regarded as the father of rheumatology in…

    Rheumatic Manifestations of Diabetes (Mimics, Common Culprits & More)

    November 11, 2024

    Understanding the intersection of diabetes mellitus & rheumatic diseases, including lesser known rheumatic entities of diabetes, such as diabetic cheiroarthropathy, scleredema & diabetic myonecrosis, is crucial for accurate diagnosis.

    What Do Diabetes, Islet Cells & Autoimmunity Have in Common?

    August 15, 2017

    “Man may be the captain of his fate, but he is also the victim of his blood sugar.” —Wilfrid Oakley, MB BChir, an early pioneer in diabetes care Perusing the list of the most notable medical achievements in the 20th century, a reader may conclude that the discovery of insulin should rank in a category…

    6 Things Endocrinologists Want Rheumatologists to Know

    May 17, 2018

    In your daily contact with rheumatology patients, you likely come across several who have type 1 or 2 diabetes. Are you doing all you can to maximize their treatment? Most physicians know about the damaging health effects of uncontrolled diabetes. From vision loss to kidney failure to nerve damage, those with diabetes require regular vigilance…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences